Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines that leverage the ubiquitin-proteasome system to treat cancer and inflammatory diseases. The company's proprietary DELigase platform enables the discovery of small molecule drugs that can target previously "undruggable" proteins by utilizing targeted protein degradation mechanisms.
Founded in 2008 and headquartered in San Francisco, Nurix went public on the NASDAQ in 2020, raising significant capital to advance its pipeline of protein degradation therapies. The company has developed multiple drug candidates targeting various oncology indications, with several programs in clinical trials. Nurix has also established strategic partnerships with major pharmaceutical companies to expand the application of its protein degradation technology across different therapeutic areas.
Nurix Therapeutics has received investment from 1 venture capital firm.
A clinical-stage biopharmaceutical company developing precision medicines using targeted protein degradation technology for cancer and inflammatory diseases.
Nurix Therapeutics has received investment from Atlas Venture. These venture capital firms and investors provide both capital and strategic support.
Nurix Therapeutics operates in the Biotech sector. A clinical-stage biopharmaceutical company developing precision medicines using targeted protein degradation technology for cancer and inflammatory diseases.
